New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis.
BACKGROUND
A new method of reduction of tumor necrosis factor alpha activity via intradermal immunization with inactivated autoleukocytes (patent UA97493 (2015) [1]) has been presented in the article. New patents from various countries have been analyzed [2-7].


OBJECTIVE
Patients with psoriasis (24) with high level of tumor necrosis factor alpha in their blood (. 30pg/ml) were immunized with autoleukocytes.


METHODS
Leukocytes were isolated by centrifuging plasma, obtained after precipitation of a patient's heparinized peripheral venous blood. Precipitate was suspended in 1.0 - 1.5ml of a patient's blood serum and 0.1ml of blood was injected into the skin of the back. For determination of autoleukocyte immunization efficacy, concentration of tumor necrosis factor alpha in a patient's blood was compared prior to immunization and at different periods after immunization.


RESULTS
In 30 days after single immunization, a considerable decrease in cytokine concentration was observed in all patients (100%); it reduced to zero in 16 out of 24 of immunized individuals (66.7%). The degree of reduction and duration of the achieved effect were individual, thus, if necessary the immunization was repeated several times. The procedure was well tolerated, and general condition of patients was improved.


CONCLUSIONS
The method of reduction of tumor necrosis factor alpha activity is recommended for implementation into clinical practice.
Department of Infectious Diseases, Danylo Halytsky National Medical University, Lviv, Ukraine, 54 Pekarska Street, 79010 L&#39;viv, Ukraine. gerab@3g.ua.
Borys A
BA
Gerasun
D000293:Adolescent; D019264:Adoptive Transfer / Q000009:adverse effects / Q000379:methods*; D000328:Adult; D015415:Biomarkers / Q000097:blood; D001804:Blood Transfusion, Autologous / Q000009:adverse effects; D015536:Down-Regulation; D005260:Female; D006801:Humans; D017708:Leukocyte Transfusion / Q000009:adverse effects / Q000379:methods*; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010330:Patents as Topic; D011565:Psoriasis / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology*; D055815:Young Adult
D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha